LLY241129C480000
- 363.02
- 0.000.00%
Eli Lilly and Co Newsroom
Hong Kong Stock Market News | Lai Kai Pharmaceuticals-B (02105) rose more than 22%, hitting a new high for the year. Recently announced clinical cooperation with eli lilly and co on a new type of weight loss drug.
The stock price of Lai Kai Pharmaceutical-B (02105) rose by over 22%, reaching a high of HK$17.4, setting a new high for the year. As of the time of publication, it has increased by 22.48%, trading at HK$17, with a turnover of 0.178 billion Hong Kong dollars.
Futu Morning News | Official announcement! Trump nominates Benset to serve as usa Secretary of the Treasury; Goldman Sachs is bullish on US stocks: the s&p 500 will rise to 7000 points.
Goldman Sachs 2025 csi commodity equity index outlook: Long gold is the "Top Trade", oil & gas prices may see a "temporary uptrend"; USA PMI in November hit the fastest level since April 2022, factories increase purchases of imported inputs; USA election settled, consumer confidence lower than expected, long-term inflation expectations breaking through the range top.
Eli Lilly's (LLY) Breakthroughs: Hedge Funds' New Healthcare Favorite
Jim Cramer on Eli Lilly and Company (LLY): 'It's Valuable'
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Novo Nordisk (NVO.US) has signed a contract with Ypsomed to manufacture the next generation of weight-loss injection pens.
Novo Nordisk A/S has announced that it has signed a contract with Ypsomed to produce the next generation of weight-loss pen.
Eli Lilly and Co (LLY.US) has submitted a fourth application for the new drug "Tirzepatide" in China.
eli lilly and co (LLY.US) has received acceptance for the new indication上市申请 of its blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection, though specific indications have not yet been disclosed.
Novo Nordisk Said to Have Contracted Ypsomed to Make Next Gen Obesity Drug's Pens
Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock
Amgen (AMGN.US) weight loss drug is poised for launch, and Wall Street is eagerly awaiting the research results.
The upcoming data from Amgen's experimental weight loss drug MariTide mid-term study will reveal the comparison of this drug with the GLP-1 drugs sold by Eli Lilly and Co and Novo-Nordisk A/S.
In 2025, the global medical care industry is expected to welcome an investment boom, with a focus on Biotech.
Jefferies Financial stated that investor sentiment in the global medical care industry has significantly warmed.
Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...
Hims & Hers Closes up 10% as Lilly Tirzepatide Compounding Dispute Resolution Delayed
Optimism Over Global Healthcare Sector Rises: Jefferies
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Nvidia Insiders Plan Big Stock Sales. CEO Jensen Huang Isn't One of Them.
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com